Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · New England Journal of Medicine · 2020 · 7.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Global burden of primary liver cancer in 2020 and predictions to 2040

Harriet Rumgay, Melina Arnold, Jacques Ferlay et al. · Journal of Hepatology · 2022 · 2.1K citations · Full text

Medicine, Oncology, Cancer Epidemiology +13

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda et al. · Journal of Hepatology · 2021 · 1.6K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy

Hiroshi Imamura, Yutaka Matsuyama, Eiji Tanaka et al. · Journal of Hepatology · 2003 · 1.6K citations

Medicine, Oncology, Carcinogenesis +16